About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Office of Surveillance and Epidemiology
›
top-articles
Office of Surveillance and Epidemiology
113
(top 1%)
papers
3.8K
(top 1%)
citations
27
(top 1%)
h
-index
61
(top 1%)
g
-index
131
all documents
4.2K
doc citations
1.5K
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
Clinical Pharmacology and Therapeutics
2011
773
2
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
JAMA - Journal of the American Medical Association
2010
445
3
Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure
Journal of Oral and Maxillofacial Surgery
2010
411
4
Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products
JAMA - Journal of the American Medical Association
2015
172
5
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
Liver International
2018
166
6
Hallucinations and Other Psychotic Symptoms Associated With the Use of Attention-Deficit/Hyperactivity Disorder Drugs in Children
Pediatrics
2009
122
7
Monitoring for Hepatotoxicity: What Is the Predictive Value of Liver “Function” Tests?
Clinical Pharmacology and Therapeutics
2009
91
8
Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients
Clinical Infectious Diseases
2013
89
9
Biomarkers for drug-induced liver injury
Expert Review of Gastroenterology and Hepatology
2010
78
10
Meta‐Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use
Clinical Infectious Diseases
2010
77
11
Impact of Pediatric Exclusivity on Drug Labeling and Demonstrations of Efficacy
Pediatrics
2014
77
12
Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications
JAMA Pediatrics
2011
75
13
Fluoroquinolone-Associated Myasthenia Gravis Exacerbation
Drug Safety
2011
67
14
Eosinophilic Pneumonia in Patients Treated with Daptomycin
Drug Safety
2012
66
15
Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series
Clinical Infectious Diseases
2019
55
16
Emergency Use Authorization for Intravenous Peramivir: Evaluation of Safety in the Treatment of Hospitalized Patients Infected With 2009 H1N1 Influenza A Virus
Clinical Infectious Diseases
2012
53
17
Appropriateness of Age Thresholds for Respiratory Syncytial Virus Immunoprophylaxis in Moderate-Preterm Infants
JAMA Pediatrics
2013
50
18
An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system
Pharmacoepidemiology and Drug Safety
2008
49
19
Progressive multifocal leukoencephalopathy after natalizumab discontinuation
Annals of Neurology
2014
49
20
Linezolid-Associated Peripheral and Optic Neuropathy in Children
Pediatrics
2011
47
21
Pediatric drug surveillance and the food and drug administration's adverse event reporting system: an overview of reports, 2003-2007
Pharmacoepidemiology and Drug Safety
2009
46
22
Opioid analgesic dose and the risk of misuse, overdose, and death: A narrative review
Pharmacoepidemiology and Drug Safety
2018
42
23
Unusual Neisseria species as a cause of infection in patients taking eculizumab
Journal of Infection
2019
37
24
Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients
JAMA - Journal of the American Medical Association
2022
34
25
Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014
Clinical Pharmacology and Therapeutics
2018
31
26
Monitoring the Safety of Medicines Used Off-Label
Clinical Pharmacology and Therapeutics
2012
30
27
US‐based emergency department visits for fluoroquinolone‐associated hypersensitivity reactions
Pharmacoepidemiology and Drug Safety
2013
30
28
Potentially inappropriate prescribing in dementia, multi-morbidity and incidence of adverse health outcomes
Age and Ageing
2021
28
29
Genetic Variants Reflecting Higher Vitamin E Status in Men Are Associated with Reduced Risk of Prostate Cancer
Journal of Nutrition
2014
27
30
Trends in oral and vaginally administered estrogen use among US women 50 years of age or older with commercial health insurance
Menopause
2018
26
31
Validation of diagnosis codes to identify hospitalized
COVID
‐19 patients in health care claims data
Pharmacoepidemiology and Drug Safety
2022
25
32
Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework
Npj Digital Medicine
2021
25
33
Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016
Journal of Clinical Endocrinology and Metabolism
2019
24
34
Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin
JAMA Internal Medicine
2021
24
35
A new algorithmic approach for the extraction of temporal associations from clinical narratives with an application to medical product safety surveillance reports
Journal of Biomedical Informatics
2016
23
36
Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink
Gut
2019
23
37
Regulatory Innovation in Postmarketing Risk Assessment and Management
Clinical Pharmacology and Therapeutics
2012
22
38
Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association
Pharmacoepidemiology and Drug Safety
2016
22
39
Oophorectomy and risk of non-alcoholic fatty liver disease and primary liver cancer in the Clinical Practice Research Datalink
European Journal of Epidemiology
2019
22
40
Pioglitazone and bladder cancer: FDA's assessment
Pharmacoepidemiology and Drug Safety
2017
21
41
“Artificial Intelligence” for Pharmacovigilance: Ready for Prime Time?
Drug Safety
2022
21
42
The Future of Population-Based Postmarket Drug Risk Assessment: A Regulator’s Perspective
Clinical Pharmacology and Therapeutics
2013
19
43
Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting
Clinical Pharmacology and Therapeutics
2021
19
44
Postmarketing Cases of Enfortumab Vedotin–Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis
JAMA Dermatology
2021
17
45
Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults
JAMA Internal Medicine
2022
17
46
Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System
Pharmacoepidemiology and Drug Safety
2018
16
47
Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021
JAMA - Journal of the American Medical Association
2022
16
48
Effectiveness of palivizumab prophylaxis in infants and children in Florida
Pharmacoepidemiology and Drug Safety
2012
15
49
Hemophagocytic lymphohistiocytosis associated with the use of lamotrigine
Neurology
2019
15
50
Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility
Drug Safety
2020
15
site/software ©
exaly
; All materials licenced under
CC by-SA
.